FDA dropping CVOT requirement for diabetes drugs

Small and medium-sized biotechs could enter diabetes space following FDA decision to drop CVOT requirement

Editor’s note: This story has been updated to reflect details contained in FDA’s guidance.

Twelve years after FDA issued draft guidance that made it exorbitantly expensive to bring a new diabetes therapy to market, the agency will no longer require cardiovascular outcomes trials either pre- or postmarket. That, in turn, could re-open the indication to small-and-medium size biotechs.

On Monday, FDA

Read the full 599 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE